ReviewHematology. American Society of Hematology. Education Program2016
Autoimmune and other acquired neutropenias.
Review in Hematology. American Society of Hematology. Education Program, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- Phenotype-specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20-year cohort study.British journal of haematology · 2026Article
- Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Diagnosis and management of neutropenia in adults: Expert guidance.British journal of haematology · 2026Review
- Increased percentages of circulating T follicular helper cells associate with disease subtype and activity in pediatric immune cytopenias.Haematologica · 2026Article
- The prevalence and influence of EBV infection in patients with severe fever with thrombocytopenia syndrome.BMC infectious diseases · 2025Article
- T-cell and autoantibody profiling for primary immune regulatory disorders.The Journal of allergy and clinical immunology · 2025Article
- Secondary Neutropenias.Biomedicines · 2025Review
- A Case of Autoimmune Neutropenia That Responded to Rituximab.Journal of medical cases · 2024Article
- Dying to Defend: Neutrophil Death Pathways and their Implications in Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity againstFrontiers in immunology · 2024Article
- A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy.Cureus · 2024Article
- Clinical significance of human neutrophil antigen-1 antibodies in children with neutropenia.International journal of hematology · 2023Article
- Review
- Article
- Neutrophil intrinsic and extrinsic regulation of NETosis in health and disease.Trends in microbiology · 2023Review
- Isolation methods determine human neutrophil responses after stimulation.Frontiers in immunology · 2023Article
- Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition.Iranian journal of public health · 2022Article
- Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.Blood advances · 2022Article
- Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.Clinical case reports · 2022Article
- Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection.Neuropsychiatric disease and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
This educational review addresses the diagnostic evaluation of patients for autoimmune and other forms of acquired neutropenia, including the futility of deconstructing the overlap of chronic "autoimmune," "benign," and "idiopathic" categories. Isolated neutropenias caused by infection, drugs, and immunologic disorders are also addressed. Discussion of management options emphasizes a conservative approach, with largely supportive care for these mostly benign and self-limited disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.